H.C. Wainwright analyst Oren Livnat assumed coverage of Tarsus Pharmaceuticals (TARS) with a Buy rating and $72 price target The firm likes the company’s Xdemvy impetus in Demodex blepharitis. Xdemvy represents the first and only FDA approved therapy to treat Demodex blepharitis, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Elanco sells royalty, milestone rights for Xdemvy to Blackstone for $295M
- Tarsus Pharmaceuticals’ Earnings Call Highlights Robust Growth
- Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- Tarsus Pharmaceuticals price target raised to $84 from $78 at Guggenheim
- Tarsus Pharmaceuticals Reports Strong Q1 2025 Growth